CU23043A1 - Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. - Google Patents

Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.

Info

Publication number
CU23043A1
CU23043A1 CU20010308A CU20010308A CU23043A1 CU 23043 A1 CU23043 A1 CU 23043A1 CU 20010308 A CU20010308 A CU 20010308A CU 20010308 A CU20010308 A CU 20010308A CU 23043 A1 CU23043 A1 CU 23043A1
Authority
CU
Cuba
Prior art keywords
epidromic
ambassation
egf
prevention
pharmaceutical composition
Prior art date
Application number
CU20010308A
Other languages
English (en)
Inventor
Acosta Jorge Berlanga
Montequin Jose I Fernandez
Perez Calixto Valdes
Perez Neobalis Franco
Constantin Ingrid Rojas
Milian Hector Santana
Corvea Larissa Chacon
Nieto Gerardo E Guillen
Martinez Luis Herrera
Frias Leonardo Canan-Haden
Perez Haydee Geronimo
Pena Jorge Sotolongo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40239814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HK05109793A priority Critical patent/HK1077740A1/xx
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20010308A priority patent/CU23043A1/es
Priority to AU2002361923A priority patent/AU2002361923B2/en
Priority to US10/499,457 priority patent/US7465704B2/en
Priority to RU2004122091/15A priority patent/RU2289424C2/ru
Priority to JP2003554215A priority patent/JP4808378B2/ja
Priority to ES02796491T priority patent/ES2322568T3/es
Priority to MXPA04005831A priority patent/MXPA04005831A/es
Priority to CA2470971A priority patent/CA2470971C/en
Priority to DE60231248T priority patent/DE60231248D1/de
Priority to PCT/CU2002/000011 priority patent/WO2003053458A1/es
Priority to UA20040705897A priority patent/UA80813C2/xx
Priority to EP02796491A priority patent/EP1466617B1/en
Priority to SI200230818T priority patent/SI1466617T1/sl
Priority to CNB02828268XA priority patent/CN1306954C/zh
Priority to KR1020047009772A priority patent/KR100795654B1/ko
Priority to DK02796491T priority patent/DK1466617T3/da
Priority to AT02796491T priority patent/ATE422897T1/de
Priority to BRPI0215214A priority patent/BRPI0215214B8/pt
Priority to PT27964915T priority patent/PT1466617E/pt
Priority to ARP020104843A priority patent/AR037824A1/es
Priority to MYPI20024760A priority patent/MY139214A/en
Publication of CU23043A1 publication Critical patent/CU23043A1/es
Priority to US12/197,001 priority patent/US7799760B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CU20010308A 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. CU23043A1 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
HK05109793A HK1077740A1 (en) 2001-12-20 2001-12-04 Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
CU20010308A CU23043A1 (es) 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
PT27964915T PT1466617E (pt) 2001-12-20 2002-12-04 Utilização de uma composição farmacêutica contendo o factor de crescimento epidérmico (egf) para prevenção da amputação do pé diabético
PCT/CU2002/000011 WO2003053458A1 (es) 2001-12-20 2002-12-04 Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético
SI200230818T SI1466617T1 (sl) 2001-12-20 2002-12-04 Uporaba farmacevtskega sestavka, ki vsebuje epidermalni rastni faktor (EGF), za preprečevanje amputacije diabetičnega stopala
RU2004122091/15A RU2289424C2 (ru) 2001-12-20 2002-12-04 Применение фармацевтической композиции, содержащей фактор эпидермального роста (ege), для предотвращения ампутации диабетической конечности
JP2003554215A JP4808378B2 (ja) 2001-12-20 2002-12-04 上皮増殖因子（ｅｇｆ）を包含する医薬組成物を用いた、糖尿病における下肢切断の予防方法
ES02796491T ES2322568T3 (es) 2001-12-20 2002-12-04 Uso de una composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
MXPA04005831A MXPA04005831A (es) 2001-12-20 2002-12-04 Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico.
CA2470971A CA2470971C (en) 2001-12-20 2002-12-04 Use of pharmaceutical composition containing epidermal growth factor (egf) for preventing diabetic limb amputation
DE60231248T DE60231248D1 (de) 2001-12-20 2002-12-04 Verwendung einer epidermalen wachstumsfaktor (egf) enthaltenden pharmazeutischen zusammensetzung zur vermeidung einer fussamputation bei diabetes
AU2002361923A AU2002361923B2 (en) 2001-12-20 2002-12-04 Use of a pharmaceutical composition containing Epidermal Growth Factor (EGF) for diabetic foot amputation prevention
UA20040705897A UA80813C2 (en) 2001-12-20 2002-12-04 Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP02796491A EP1466617B1 (en) 2001-12-20 2002-12-04 Use of a pharmaceutical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention
US10/499,457 US7465704B2 (en) 2001-12-20 2002-12-04 Methods for enhancing healing of diabetic foot ulcers by injecting epidermal growth factor (EGF)
CNB02828268XA CN1306954C (zh) 2001-12-20 2002-12-04 表皮生长因子在制备预防糖尿病肢端坏疽截肢的注射用药物组合物中的用途
KR1020047009772A KR100795654B1 (ko) 2001-12-20 2002-12-04 당뇨성 발 절단 예방을 위한 표피성장인자 함유 약제학적조성물의 용도
DK02796491T DK1466617T3 (da) 2001-12-20 2002-12-04 Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation
AT02796491T ATE422897T1 (de) 2001-12-20 2002-12-04 Verwendung einer epidermalen wachstumsfaktor (egf) enthaltenden pharmazeutischen zusammensetzung zur vermeidung einer fussamputation bei diabetes
BRPI0215214A BRPI0215214B8 (pt) 2001-12-20 2002-12-04 uso do fator de crescimento epidérmico, e, composição farmacêutica
ARP020104843A AR037824A1 (es) 2001-12-20 2002-12-13 Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para la prevencion de la amputacion del pie diabetico; y composicion farmaceutica
MYPI20024760A MY139214A (en) 2001-12-20 2002-12-18 Use of pharmaceutical composition containing epidermal growth factor (egf) for preventing diabetic limb amputation
US12/197,001 US7799760B2 (en) 2001-12-20 2008-08-22 Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010308A CU23043A1 (es) 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.

Publications (1)

Publication Number Publication Date
CU23043A1 true CU23043A1 (es) 2005-05-20

Family

ID=40239814

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010308A CU23043A1 (es) 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.

Country Status (22)

Country Link
US (2) US7465704B2 (es)
EP (1) EP1466617B1 (es)
JP (1) JP4808378B2 (es)
KR (1) KR100795654B1 (es)
CN (1) CN1306954C (es)
AR (1) AR037824A1 (es)
AT (1) ATE422897T1 (es)
AU (1) AU2002361923B2 (es)
BR (1) BRPI0215214B8 (es)
CA (1) CA2470971C (es)
CU (1) CU23043A1 (es)
DE (1) DE60231248D1 (es)
DK (1) DK1466617T3 (es)
ES (1) ES2322568T3 (es)
HK (1) HK1077740A1 (es)
MX (1) MXPA04005831A (es)
MY (1) MY139214A (es)
PT (1) PT1466617E (es)
RU (1) RU2289424C2 (es)
SI (1) SI1466617T1 (es)
UA (1) UA80813C2 (es)
WO (1) WO2003053458A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
CU23529A1 (es) * 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
CN101496486B (zh) * 2009-03-13 2011-02-16 新疆巴音郭楞蒙古自治州农业科学研究所 一种蘑菇栽培方法
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
ES2468740B1 (es) 2012-11-13 2015-04-01 Consejo Superior De Investigaciones Científicas (Csic) Apósito para cicatrización de heridas comprometidas
EP3035903B1 (en) 2013-08-20 2018-08-22 Anutra Medical, Inc. Syringe fill system and method
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CN104173366A (zh) * 2014-09-14 2014-12-03 陈钏黄 一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用
MX2016016339A (es) * 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
WO2019006127A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE RENAL CELL
WO2019006113A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE CEREBRAL CELL
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético
WO2022060178A1 (ko) 2020-09-21 2022-03-24 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR102581240B1 (ko) 2020-09-21 2023-09-22 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR20230146379A (ko) 2022-04-12 2023-10-19 고려대학교 산학협력단 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
CA2013770A1 (en) 1989-04-04 1990-10-04 Jack M. Shaw Use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
EP0437577A1 (en) 1989-08-01 1991-07-24 The University Of Michigan Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
EP0564502B1 (en) * 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
CN1160582A (zh) * 1996-12-27 1997-10-01 暨南大学生物工程研究所 含有细胞生长因子的皮肤外用组合物
WO2002009738A1 (en) * 2000-07-28 2002-02-07 Murphy Christopher J Transplant media
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用

Also Published As

Publication number Publication date
CN1306954C (zh) 2007-03-28
US7799760B2 (en) 2010-09-21
KR100795654B1 (ko) 2008-01-21
SI1466617T1 (sl) 2009-08-31
DE60231248D1 (de) 2009-04-02
MY139214A (en) 2009-08-28
BR0215214A (pt) 2004-12-07
ATE422897T1 (de) 2009-03-15
DK1466617T3 (da) 2009-06-15
CA2470971C (en) 2011-02-01
AU2002361923B2 (en) 2006-02-02
MXPA04005831A (es) 2004-09-13
UA80813C2 (en) 2007-11-12
EP1466617B1 (en) 2009-02-18
EP1466617A1 (en) 2004-10-13
ES2322568T3 (es) 2009-06-23
RU2004122091A (ru) 2005-04-10
JP4808378B2 (ja) 2011-11-02
KR20040094669A (ko) 2004-11-10
HK1077740A1 (en) 2006-02-24
US20050107294A1 (en) 2005-05-19
JP2005516024A (ja) 2005-06-02
AR037824A1 (es) 2004-12-09
AU2002361923A1 (en) 2003-07-09
PT1466617E (pt) 2009-05-20
RU2289424C2 (ru) 2006-12-20
BRPI0215214B8 (pt) 2021-05-25
US20080312139A1 (en) 2008-12-18
WO2003053458A1 (es) 2003-07-03
CN1620308A (zh) 2005-05-25
BRPI0215214B1 (pt) 2017-05-30
US7465704B2 (en) 2008-12-16
CA2470971A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
CU23043A1 (es) Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
CL2008000762A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
PT1086706E (pt) Composicao estabilizada que compreende um medicamento nootropico
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
AR028313A1 (es) Un procedimiento para la produccion de una composicion desodorante o antitranspirante
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
ID26055A (id) Senyawa-senyawa hidroksidifenil eter
DE602004012440D1 (de) Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
AU2002343661A1 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
WO2004039326A3 (en) Propofol with cysteine
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
WO2003020963A3 (en) Proteins in type 2 diabetes
DE50209948D1 (de) Verwendung von Scopinester Derivaten zur Herstellung von Arzneimitteln
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE402719T1 (de) Injiziebare pharmazeutische zusammensetzung enthaltend ethanol zur behandlung von bandscheibenvorfällen
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE602004016751D1 (de) Orodispersible pharmazeutische zusammensetzung einer antithrombotischen verbindung